Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pandox and Eiendomsspar submit possible offer for Dalata Hotel Group

(Sharecast News) - Shares in Irish hotels operator Dalata Hotel Group were up double digits in early trading after a consortium including hotel property company Pandox submitted a possible offer for the firm. Pandox, which teamed up with real estate outfit Eiendomsspar, made an all-cash offer of €6.05 per ordinary share to acquire Dalata, valuing the business behind the Maldron and Clayton Hotel brands at €1.3bn.

Eiendomsspar already holds a beneficial interest in approximately 8.8% Dalata's ordinary shares and the consortium expects to form a company that will be indirectly owned or controlled by Pandox and Eiendomsspar for the purposes of the implementation of the proposal.

The consortium noted that Dalata was currently engaged in a formal sale process and pointed out that it has not participated in that process to date. However, it believes its proposal will deliver "tangible and certain value" for Dalata shareholders, fully in cash and at a "meaningful premium".

Pandox and Eiendomsspar said: "As established hotel investors with deep knowledge of the European hospitality sector, and experience from successfully executing similar transactions in the UK and Ireland, the consortium is well-positioned to support Dalata's business and long-term growth ambitions.

"The consortium is currently in negotiations with a reputable European hotels' operator to conclude a framework agreement for the operation of the Dalata hotels should the consortium acquire Dalata. Such operator shares the consortium's commitment to long-term profitable and sustainable growth."

As of 1010 BST, Dalata shares were up 10.87% at 520.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.